Ultragenyx Pharmaceutical Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (59)

Latest Posts

About This Stock More About This Stock
3 BioTech Stocks To Buy On The Dip
Article By: StockNews
Tuesday, November 17, 2020 10:37 AM EDT
Pfizer, Inc. and BioNTech SE’s vaccine news has created significant pressure on other biotech companies to launch their covid-19 vaccines or therapies soon.
In this article: ALXN, RARE, BNTX
Read
Ultragenyx Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters’ Option To Purchase Additional Shares
Article By: NASDAQ GlobeNewswire
Monday, November 2, 2020 2:22 PM EDT
Ultragenyx Pharmaceutical Inc., today announced the closing of its previously announced underwritten public offering of 5,111,110 shares of its common stock, including the exercise in full by the underwriters of their option.
In this article: RARE
Read
The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke, And Ultragenyx
Article By: Benzinga
Sunday, June 14, 2020 3:13 PM EDT
Biotech stocks came under pressure along with the broader market in the week that ended June 12, as a worsening pandemic situation and its impact on the economy led to an across-the-board sell-off in the global markets.
In this article: MRK, EVOK, RARE, EPZM Also: AZN, GILD, BMY, SNY, RPRX, CELG, PRQR, NBRV, CBIO, UROV, CNTG
Read
Small Cap Biotechs Lead The Market In 2019 Up 20% YTD
Article By: Rod Raynovich
Thursday, February 28, 2019 12:20 PM EDT
Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%.
In this article: ONCE, RARE, DHR, GE, XBI, BLUE, CRSP, IWM, XLV, MRK, RHHBY, BMY, CELG, LOXO, LLY, GNMK, AMRN, TDOC
Read
Ultragenyx Pharmaceutical Reports Positive Phase III Data For Their Kyowa Hakko Kirin-Partnered Drug
Article By: Lorimer Wilson
Thursday, April 20, 2017 2:54 AM EDT
Ultragenyx Pharmaceutical Inc. has reported clearly positive Phase III data for their Kyowa Hakko Kirin-partnered drug for X-linked hypophosphatemia, and now they plan to hustle that data package to regulators at the FDA and EMA.
In this article: RARE
Read

Latest Tweets for $RARE

No tweets yet!